Alnylam Pharmaceuticals
Open
$282.93
Prev. Close
$283.00
High
$283.43
Low
$282.33
Market Snapshot
$37.51B
65.0
-2.17
$2.25B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Recently from Cashu
Alnylam Pharmaceuticals Partners with Inceptive Nucleics for $2 Billion AI-Driven Drug Discovery Initiative
Alnylam Pharmaceuticals (Ticker: ALNY) forges a groundbreaking partnership with Inceptive Nucleics valued up to $2 billion, aiming to transform drug discovery through artificial intelligence. This col…
Alnylam Pharmaceuticals Partners with Inceptive Nucleics to Enhance RNAi Drug Discovery Using AI
Alnylam Pharmaceuticals (Ticker: ALNY), a leader in RNA interference (RNAi) therapeutics, forges a transformative collaboration with Inceptive Nucleics that could reshape its research landscape. This…
Alnylam Pharmaceuticals Expands Board to Enhance Governance Amidst RNAi Technology Challenges
Alnylam Pharmaceuticals (Ticker: ALNY) transforms its Board of Directors by expanding from ten to eleven members, reflecting its commitment to strengthening governance as it navigates challenges in it…
Alnylam Pharmaceuticals Innovates RNAi Therapeutics Amid Economic Volatility and Market Challenges
Alnylam Pharmaceuticals: Pioneering RNAi Therapeutics in a Volatile Market Landscape Amidst the recent volatility in financial markets, Alnylam Pharmaceuticals continues to innovate within the biophar…